Influx Healthtech Ltd Q3 FY26 Earnings Analysis

- Post-expansion, Influx Healthtech expects a 2.5x increase in capacity based on FY25 figures, aiming to reach approximately INR 500 crores in topline within 2.5 to 3 years (FY27-FY28 timeframe). - Annual revenue growth is expected to continue at a similar pace of 20%-25% with ongoing machinery installations and new product lines (beverage and pet food). - The pet food segment will increase capacity by 10x, significantly boosting output. - The beverage line, including carbonation and RTD (ready-to-drink) nutritional drinks, is anticipated to scale up gradually after successful pilot exports. - The veterinary segment is projected to grow strongly over 5-10 years, potentially paralleling nutraceutical growth. - Expansion plans include innovative new machines, expanding cosmetics, veterinary, and beverage segments, diversifying beyond the core nutraceutical business. - Capacity utilization is currently increasing (nutraceuticals ~65%-70%), with further expansion aligned with order flows to sustain growth.

- The company expects a topline of INR 500 crores post a 2.5x capacity expansion, likely achieved in 2.5 to 3 years (FY27-FY28). - Capacity utilization and production are anticipated to increase steadily, with a 20%-25% capacity increase expected by January 2026. - EBITDA margins are expected to be sustainable over the next three years, with confidence in maintaining or improving current profitability. - Long-term fixed asset turnover is targeted at 5 to 6 times, indicating operational efficiency growth. - Expansion into new segments like beverage (RTD nutritional drinks), pet food (10x capacity growth), cosmetics, and veterinary supplements is expected to diversify revenue and boost growth. - Internal accruals are driving capacity expansions, avoiding large debts and ensuring sustainable growth. - The company aims to double revenue by FY27 while steadily increasing capacity and ramping up production lines.

- Capex from IPO proceeds planned: approx. INR 20-23 Cr for nutraceuticals and INR 11 Cr for veterinary (FY26-FY27). - By H1 FY27, most IPO funds expected to be utilized. - Machinery orders include beverage line (10,000 bottles/hour), pet food line (1,000 kg/hour), and retort plant. - Installation timelines: beverage and pet food machinery expected operational by January 2026; overall new factory operational by H1 FY26 (May-June 2026), delayed slightly due to rains. - Internal accruals augmenting capacity expansion; about INR 11.7 Cr capex done by H1 FY26. - Future plans to add innovative, automized machines after current expansion. - Spare land (~90,000 sq ft) available for further expansion beyond current IPO-funded capacity growth. - Strategic focus on entering nutrition-focused RTD beverages, veterinary supplements (including turtle and camel foods), and expanding pet food segment.

- The company currently has no short-term borrowings and is debt-free. - There is no immediate plan for any borrowings as the company has not yet fully utilized its IPO funds. - IPO funds, amounting to around INR 25-33 crores, are parked safely and being gradually used for capex and expansion. - The management emphasized transparency and openness for any future queries regarding fundraising but did not indicate any new fundraising plans. - There were no mentions or indications of future fundraising through debt or equity during the call. - Focus remains on utilizing IPO funds effectively for capacity expansion, machinery orders, and infrastructure setup without resorting to new borrowings.

- The company is experiencing strong demand with many opportunities and no risk of losing sales currently, indicating a healthy order pipeline. - Orders are robust across segments, with clients expanding and requiring increased capacity. - There is ongoing export activity, including shipments to Caribbean Islands and African markets like Tanzania, Nigeria, and Kenya. - The company is optimistic about scaling up production, especially with new machinery for beverage lines and pet food. - Export orders to Africa are growing steadily, supported by regulatory approvals like the Tanzania audit scheduled for December 2025. - The firm has backlog related to new automated plants and equipment installation, expected to enhance capacity by 2.5x post-IPO fund utilization. - While exact orderbook figures are not disclosed, management indicates a positive outlook supported by increasing capacity and export market growth.